Absci (ABSI)

• Market cap: $570M
• 1 day: -4.43%
• 5 days: -2.55%
• 1 month: 54.04%
• 3 months: 94.51%
• 6 months: 14.02%
• Year to date: 83.03%
• 1 year: 0.81%
• 5 years: -77.03%
• 10 years: -77.03%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 156

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

121% more call options, than puts

Call options by funds: $850K | Put options by funds: $384K

50% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 22

27% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 33

7% more funds holding

Funds holding: 122 [Q3] → 130 (+8) [Q4]

0.52% more ownership

Funds ownership: 63.79% [Q3] → 64.31% (+0.52%) [Q4]

30% less capital invested

Capital invested by funds: $277M [Q3] → $194M (-$83.2M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 1% upside
• Avg. target: $7.75 56% upside
• High target: $10 102% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Needham Gil Blum 22% 1-year accuracy 36 / 167 met price target	81% upside $9	Buy Initiated	22 Jan 2025
HC Wainwright & Co. Swayampakula Ramakanth 38% 1-year accuracy 74 / 194 met price target	41% upside $7	Buy Reiterated	17 Jan 2025
Keybanc Scott Schoenhaus 67% 1-year accuracy 24 / 36 met price target	1% upside $5	Overweight Maintained	8 Jan 2025
Guggenheim Vamil Divan 50% 1-year accuracy 12 / 24 met price target	102% upside $10	Buy Reiterated	3 Dec 2024